Sign inJoin waitlistJoin the waitlist

DT

David Tuveson

J. Zuckerberg Professor of Cancer Research · Temple University Hospital

Credentials: · · · ·

History

Temple University Hospital
Present

Medical Oncology
Internal Medicine

Research

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
New England Journal of Medicine · 2002 · 3,431 citations
A framework for advancing our understanding of cancer-associated fibroblasts
Review · Nature reviews. Cancer · 2020 · 3,123 citations
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer
Science · 2009 · 2,653 citations

Ralph Hruban
17 papers
Sunil Hingorani
16 papers
CI
Christine Iacobuzio-Donahue
10 papers
Kenneth Yu
9 papers
Anirban Maitra
8 papers · 2 as a fellow
Carlos Arteaga
7 papers
Cheryl Willman
7 papers
DK
Daniel King
7 papers
JC
James Crawford
7 papers
Louis Weiner
7 papers
RB
Richard Burkhart
7 papers
Ruben Mesa
7 papers

Grants

CSHL Cancer Center Support Grant
National Cancer Institute · P30
Contact PI · $49.1M · Cold Spring Harbor Laboratory
1997–2031
SOAT1 as a Targetable Dependency in Pancreatic Adenocarcinoma
National Cancer Institute · R01
Contact PI · $1.6M · Cold Spring Harbor Laboratory
2025–2030
Discovery of Natural Products and Natural Product Derivatives as Inhibitors of KLK6 to Prevent the Progression of Preneoplastic Ductal Pancreatic Cancer
National Cancer Institute · UG3
PI · $796.8K · Cold Spring Harbor Laboratory
2025–2028
Fibroblast Heterogeneity in Pancreatic Cancer
National Cancer Institute · R01
Contact PI · $3.9M · Cold Spring Harbor Laboratory
2021–2026

Clinical trials

Famotidine Outpatient COVID-19 Treatment Study
Principal investigator · Completed
Northwell Health
2020
Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)
Principal investigator · Terminated · Phase 2
Lisa Bax
2011–2012